Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Neurology

What Blood Tests Are Recommended for Suspected CIDP?

At a Glance

No blood test alone can diagnose CIDP. Neurologists use blood tests such as glucose, B12, and monoclonal protein screening to find other causes that can mimic CIDP, then interpret results with the examination and nerve conduction studies.

In this answer

3 sections

01

The Baseline Workup (Commonly Recommended)

02

Why Monoclonal Protein Testing is Important

03

Symptom-Driven and Targeted Testing

No single blood test can diagnose Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [1]. The diagnosis is based primarily on a neurologist’s clinical examination and nerve conduction studies that show electrical patterns compatible with myelin sheath damage [2]. However, because several other conditions can cause similar symptoms or resemble the nerve damage seen in CIDP, a targeted blood workup is a critical part of the diagnostic process [1] [2]. The goal of these blood tests is to look for alternative causes (mimics) that require different treatments, and to identify any coexisting health issues [2].

Normal blood tests do not rule out CIDP, and an abnormal result does not automatically prove a different disease is causing your symptoms. Your neurologist will interpret the results alongside your physical exam and nerve studies.

Quick Reference: Blood Tests in Suspected CIDP

Test Category What It Looks For When It Is Usually Considered
Glucose / HbA1c Diabetes or impaired blood sugar. Routine baseline; helps interpret nerve conduction studies [3].
CBC, CMP, B12 Anemia, kidney/liver function, B12 deficiency. Routine baseline; checks general health and common neuropathy causes [4] [2].
Paraprotein Screen (SPEP/IFE, Free Light Chains) Abnormal “M-proteins” produced by the immune system. Routine baseline; screens for conditions like MGUS, anti-MAG, or POEMS [5] [6].
Anti-MAG Antibodies Antibodies attacking myelin-associated glycoprotein. Targeted; considered if an IgM M-protein is found [7].
VEGF Elevated growth factor linked to POEMS syndrome. Targeted; considered if an M-protein is found alongside specific systemic symptoms (e.g., swelling, skin changes) [8].
Infections / Autoimmune (HIV, Hep B/C, ANA) Infections or systemic autoimmune diseases (like lupus). Targeted; based on local prevalence, risk factors, or systemic symptoms [9] [10].
Nodal/Paranodal Antibodies (NF155, CNTN1) Antibodies targeting specific parts of the nerve (nodes). Specialist testing; considered for atypical features like severe tremor, kidney involvement, or poor treatment response [11] [12].

There is no universal panel required for every single person, but when evaluating suspected CIDP, neurologists commonly order a baseline set of blood tests.

  • Complete Blood Count (CBC) and Comprehensive Metabolic Panel (CMP): These check for anemia, kidney function, and liver health. While abnormalities like anemia can occur in people with CIDP, they may also point toward other systemic conditions causing the neuropathy [4].
  • Glucose and HbA1c: Diabetes is a leading cause of nerve damage. High blood sugar doesn’t rule out CIDP—in fact, diabetes and CIDP can coexist [3]. However, diabetic neuropathy can cause changes on nerve conduction studies that resemble demyelination, making it harder to interpret the tests accurately [3] [13].
  • Vitamin B12: Screening for B12 deficiency is often done because severe deficiency can damage the nerves and spinal cord, causing symptoms that might initially look similar to a demyelinating neuropathy [2].
  • Paraprotein Screening: Abnormal proteins in the blood are linked to several conditions that mimic CIDP, so doctors typically order serum protein electrophoresis with immunofixation, quantitative immunoglobulins, and serum free light chains [5] [6].

Why Monoclonal Protein Testing is Important

Up to 29% of patients evaluated in some CIDP clinics are found to have a paraprotein, also known as a monoclonal protein or “M-protein” [4] [5]. Finding an M-protein does not automatically mean you have cancer or that the protein is causing your neuropathy; it is often a benign condition called MGUS (Monoclonal Gammopathy of Undetermined Significance) that simply becomes more common as people age [14] [15].

However, detecting it is important because it prompts your doctor to evaluate you for paraproteinemic neuropathies, which can overlap with CIDP electrodiagnostically but have different clinical patterns [6].

  • IgM Proteins: If the M-protein is the IgM type, your doctor may test for anti-MAG antibodies. Anti-MAG neuropathy is a distinct condition that often causes a slow, distal (hands and feet) sensory neuropathy with tremors [7] [16].
  • POEMS Syndrome and AL Amyloidosis: If an M-protein is accompanied by other specific symptoms—such as severe swelling (edema), skin changes, enlarged organs, elevated platelets, or bone lesions—it may point to POEMS syndrome or AL amyloidosis [17] [6]. In these cases, a targeted test for VEGF (Vascular Endothelial Growth Factor) may be ordered, and a hematology referral is often appropriate to help investigate the finding [8] [6].

Symptom-Driven and Targeted Testing

Depending on your medical history, geographic location, and specific symptoms, your neurologist may order additional tests.

  • Infectious Disease Testing: HIV can cause neuropathies that resemble CIDP [9] [5]. HIV testing is recommended when clinically indicated, especially in areas with high prevalence [9]. Hepatitis B and C have also been associated with CIDP-like neuropathies and may be checked depending on your risk factors [18] [19].
  • Autoimmune Panels: If you have systemic symptoms like joint pain, kidney problems, or unexplained rashes, your doctor may check for markers of lupus (such as ANA and dsDNA) or Sjögren’s syndrome (such as anti-SSA/Ro) [10] [20].
  • Nodal and Paranodal Antibodies: If your neuropathy comes on very rapidly, features severe tremors or unsteadiness, includes kidney protein leakage (nephrotic syndrome), or fails to respond to standard CIDP treatments, your doctor might test for specialized antibodies like anti-NF155 or anti-CNTN1 [11] [12]. Testing positive for these may support a diagnosis of an autoimmune nodopathy [11]. This is a separate disease from CIDP that may change treatment discussions, as standard IVIG is often less effective and alternatives like rituximab might be considered by a specialist [21] [12].

Common questions in this guide

Can a blood test confirm that I have CIDP?
No single blood test can confirm CIDP. Doctors mainly use a neurologic examination and nerve conduction studies to assess for CIDP, while blood tests help identify other conditions that can cause similar symptoms or test results. Normal blood tests do not rule out CIDP.
Which blood tests are usually ordered first for suspected CIDP?
Common baseline tests include a complete blood count, a metabolic panel, blood glucose or HbA1c, vitamin B12, and testing for abnormal blood proteins. Protein testing may include serum protein electrophoresis with immunofixation, quantitative immunoglobulins, and serum free light chains. The exact tests depend on your symptoms and medical history.
Why is monoclonal protein testing important in a CIDP evaluation?
Monoclonal protein testing looks for abnormal proteins that can be associated with conditions such as MGUS or other nerve disorders that resemble CIDP. Finding an M-protein does not automatically mean you have cancer or that it is causing your symptoms. Additional evaluation may be needed to determine its significance.
When might I need anti-MAG or VEGF blood testing?
Anti-MAG antibody testing may be considered when testing finds an IgM monoclonal protein, especially with a slowly progressive sensory neuropathy or tremor. VEGF testing may be considered when a monoclonal protein occurs with findings such as swelling, skin changes, enlarged organs, or other features that raise concern for POEMS syndrome.
Should blood tests check for infections or autoimmune diseases?
Tests for HIV, hepatitis B or C, lupus, or Sjögren syndrome may be appropriate when your risk factors, geographic setting, or symptoms suggest one of these conditions. Joint pain, rashes, kidney problems, or other symptoms outside the nerves can help guide testing. These conditions can cause neuropathy or symptoms that resemble CIDP.
When are NF155 or CNTN1 antibody tests considered?
Specialized nodal or paranodal antibody tests may be considered when symptoms begin rapidly, severe tremor or unsteadiness is present, kidney protein leakage occurs, or standard CIDP treatment does not work well. Positive results may support an autoimmune nodopathy, which is a separate condition and can change treatment discussions.

Related questions

How Long Does It Take to Recover from CIDP Treatment? How Common Is CIDP, and Who Is Most Likely to Get It? Is Nerve Damage From CIDP Permanent or Reversible? Can You Eventually Stop CIDP Treatment and Reach Remission? NF155, CNTN1 & CASPR1: What Do They Mean for Treatment?
Show more
How Does CIDP Differ From Diabetic Neuropathy? Explained What Is the IVIG Wear-Off Effect in CIDP Treatment? Why Is a Lumbar Puncture Needed to Help Diagnose CIDP? How Is CIDP Different From ALS, CMT, MMN, and POEMS? Can CIDP Cause One-Sided Symptoms? MADSAM Explained What Is the Difference Between Anti-MAG Neuropathy and CIDP? How CIDP Variants Affect Your Treatment and Prognosis What Causes CIDP, and Can Infections or Vaccines Trigger It? What Should You Do If IVIg or Steroids Fail for CIDP? Autoimmune Nodopathies vs CIDP: What Are the Symptoms? Does CIDP Shorten Life Expectancy? Prognosis Explained Why Is Physical Therapy Important for CIDP Recovery? How Does Efgartigimod (Vyvgart) Work for CIDP Treatment? Is CIDP Hereditary or Contagious? Passing It to Children How Is CIDP Diagnosed and How Long Does Diagnosis Take? Can You Have CIDP With a Borderline or Normal Nerve Study? Can MRI or Ultrasound Diagnose CIDP When Tests Are Unclear? How Do Doctors Distinguish Acute-Onset CIDP From GBS? When Should CIDP, Anti-MAG, or Protein Tests Be Done? Do I Need a Nerve Biopsy or Genetic Test for CIDP? Can You Have CIDP Without Muscle Weakness? Explained

Get notified when new evidence is published on Chronic inflammatory demyelinating polyneuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (21)
  1. 1

    European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.

    Van den Bergh PYK, van Doorn PA, Hadden RDM, et al.

    European journal of neurology 2021; (28(11)):3556-3583 doi:10.1111/ene.14959.

    PMID: 34327760
  2. 2

    Chronic inflammatory demyelinating polyradiculoneuropathy-Diagnostic pitfalls and treatment approach.

    Stino AM, Naddaf E, Dyck PJ, Dyck PJB

    Muscle & nerve 2021; (63(2)):157-169 doi:10.1002/mus.27046.

    PMID: 32914902
  3. 3

    Nerve ultrasound helps to distinguish CIDP patients with diabetes from patients with diabetic polyneuropathy.

    Heiling B, Kneer K, He W, et al.

    Scientific reports 2024; (14(1)):30504 doi:10.1038/s41598-024-82235-8.

    PMID: 39681614
  4. 4

    Frequent laboratory abnormalities in CIDP patients.

    Abraham A, Albulaihe H, Alabdali M, et al.

    Muscle & nerve 2016; (53(6)):862-5 doi:10.1002/mus.24978.

    PMID: 26576014
  5. 5

    History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

    Dyck PJB, Tracy JA

    Mayo Clinic proceedings 2018; (93(6)):777-793 doi:10.1016/j.mayocp.2018.03.026.

    PMID: 29866282
  6. 6

    Paraproteinemia and neuropathy.

    Koike H, Katsuno M

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(11)):4489-4501 doi:10.1007/s10072-021-05583-7.

    PMID: 34529193
  7. 7

    Optimizing Anti-Myelin-Associated Glycoprotein and IgM-Gammopathy Testing for Neuropathy Treatment Evaluation.

    Klein CJ, Triplett JD, Murray DL, et al.

    Neurology 2024; (103(11)):e210000 doi:10.1212/WNL.0000000000210000.

    PMID: 39499873
  8. 8

    Early VEGF testing in inflammatory neuropathy avoids POEMS syndrome misdiagnosis and associated costs.

    Marsh ES, Keddie S, Terris-Prestholt F, et al.

    Journal of neurology, neurosurgery, and psychiatry 2021; (92(2)):172-176 doi:10.1136/jnnp-2020-324012.

    PMID: 33106368
  9. 9

    CIDP in a HIV endemic population: A prospective case series from Johannesburg, South Africa.

    Mochan A, Anderson D, Modi G

    Journal of the neurological sciences 2016; (363()):39-42.

    PMID: 27000218
  10. 10

    Chronic inflammatory demyelinating polyradiculoneuropathy associated with systemic lupus erythematosus.

    Julio PR, Cortês MMM, Costallat LTL, et al.

    Seminars in arthritis and rheumatism 2021; (51(1)):158-165 doi:10.1016/j.semarthrit.2020.09.018.

    PMID: 33383292
  11. 11

    Autoimmune nodopathies: a clinical review.

    Doppler K, Sommer C

    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2026; (191()):2112341 doi:10.1016/j.clinph.2026.2112341.

    PMID: 42492459
  12. 12

    Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera.

    Delmont E, Brodovitch A, Kouton L, et al.

    Journal of neurology 2020; (267(12)):3664-3672 doi:10.1007/s00415-020-10041-z.

    PMID: 32676765
  13. 13

    Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy.

    Doneddu PE, Cocito D, Manganelli F, et al.

    Journal of neurology, neurosurgery, and psychiatry 2020; (91(10)):1092-1099 doi:10.1136/jnnp-2020-323615.

    PMID: 32868387
  14. 14

    Advances in the Treatment of Paraproteinemic Neuropathy.

    Nobile-Orazio E, Bianco M, Nozza A

    Current treatment options in neurology 2017; (19(12)):43 doi:10.1007/s11940-017-0479-9.

    PMID: 29034435
  15. 15

    Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?

    Steiner N, Schwärzler A, Göbel G, et al.

    Oncotarget 2017; (8(3)):5081-5091 doi:10.18632/oncotarget.13861.

    PMID: 27974705
  16. 16

    Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy.

    Pascual-Goñi E, Martín-Aguilar L, Lleixà C, et al.

    Scientific reports 2019; (9(1)):6155 doi:10.1038/s41598-019-42545-8.

    PMID: 30992531
  17. 17

    Distinctive patterns of peripheral neuropathy across the spectrum of plasma cell disorders.

    Byun JM, Kwon YN, Koh Y, et al.

    Scientific reports 2019; (9(1)):16769 doi:10.1038/s41598-019-53289-w.

    PMID: 31727997
  18. 18

    Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease.

    Rodríguez Y, Vatti N, Ramírez-Santana C, et al.

    Journal of autoimmunity 2019; (102()):8-37 doi:10.1016/j.jaut.2019.04.021.

    PMID: 31072742
  19. 19

    Hepatitis B Precipitating Neurological Complications: A Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Conundrum.

    Krishnan G, Chandrasekar KK, Natarajan GK

    Cureus 2024; (16(2)):e53551 doi:10.7759/cureus.53551.

    PMID: 38445132
  20. 20

    Chronic inflammatory demyelinating polyradiculoneuropathy associated with Sjögren`s syndrome in a child.

    Süt NY, Kartal AT, Ertem Ş, et al.

    The Turkish journal of pediatrics 2023; (65(1)):155-160.

    PMID: 36866997
  21. 21

    Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype.

    Cortese A, Lombardi R, Briani C, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2020; (7(1)) doi:10.1212/NXI.0000000000000639.

    PMID: 31753915

This page explains blood tests used when CIDP is suspected for informational purposes only and does not constitute medical advice. A neurologist should interpret your results alongside your examination and nerve conduction studies.